 |
|
|
| |
PRECLINICAL CHARACTERISATION OF MIV-802, A NOVEL URIDINE NUCLEOTIDE HCV NS5B POLYMERASE INHIBITOR, FOR TREATMENT OF HEPATITIS C VIRUS INFECTION
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Annelie Lindqvist 1 , Helen Kylefjord 1, Horst Wähling 1, Sanja Juric 1, Staffan Torssell 1, Gennadiy Kalayanov 1, Lotta Vrang 1, Emily Hoberg 2, Claes Gustafsson 2, Matthias Gotte3, Anders Eneroth 1, Erik Lindström 1, Kristina Wikström 1, Paul Targett-Adams1, Pedro Pinho 1, Richard Bethell 1, Åsa Rosenquist* 1
1Medivir, Huddinge, Sweden. 2Dept. of Biochem and Cell Biology, University of Gothenburg, Gothenburg, Sweden. 3Department of Medical Microbiology & Immunology, University of Alberta, Edmonton (Alberta), Canada.
Contact: asa.rosenquist@medivir.se
|
| |
|
|
|
|
|
